4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis
1991
4-Hydroxyandrostenedione and Breast Cancer Prevention in Rats
Sample size: 170
publication
Evidence: high
Author Information
Author(s): R.C. Coombes, J.R. Wilkinson, J.M. Bliss, P. Shah, D.F. Easton, M. Dowsett
Primary Institution: Medical Oncology Unit, St George's Hospital Medical School
Hypothesis
Can 4-hydroxyandrostenedione (4-OHA) prevent mammary tumourigenesis in rats?
Conclusion
4-OHA is effective in preventing carcinogen-induced mammary tumours in rats.
Supporting Evidence
- 4-OHA reduced tumour incidence over a 30 week period compared to controls.
- Continuing therapy showed marginal benefit in tumour-free survival.
- At 30 weeks, 100% of rats treated with 4-OHA were alive compared to 57% of controls.
Takeaway
This study shows that a drug called 4-OHA can help stop rats from getting breast cancer caused by a chemical.
Methodology
Rats were treated with 4-OHA and monitored for tumour development over 30 to 60 weeks.
Limitations
The study was conducted on rats, and results may not directly translate to humans.
Participant Demographics
Female Ludwig/Wistar/Olac rats
Statistical Information
P-Value
<0.0005
Confidence Interval
95% CI 39%, 73%
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website